Peter Hagedorn

I have a MSc in biophysics from the Niels Bohr Institute, University of Copenhagen, and a PhD in molecular biology from Risø National Laboratory and the University of Southern Denmark. I am interested in developing predictive science methods for drug discovery. I have previously worked as a research scientist at AstraZeneca and LEO Pharma. Currently I work as a research scientist at Santaris Pharma funded through COAT (linkedin).

In COAT, as part of Morten Lindows group, my role is to bridge and integrate the knowledge and data generated by the academic COAT partners and Santaris Pharma scientists, respectively.

The projects I currently work on include

  • Collecting and standardizing Santaris Pharma research data in a machine-readable format that allows easy retrieval and meta-analysis (together with Stine Møllerud).
  • Developing approaches to oligonucleotide sequence analysis. This includes encoding the oligonucleotides in a manner that allows machine-learning tools to be applied (together with Victor Yakimov). With such tools, we attempt to predict complex properties of oligonucleotides such as potency and toxic potentials.
  • Developing models of oligonucleotides, including kinetic models of RNAse H-recruiting- (together with Lykke Pedersen), and microRNA blocking oligonucleotides, as well as nearest-neighbor models to predict melting temperatures.
  • Exploring oligonucleotide binding and specificity. Ideally, therapeutic oligonucleotides should only affect their target transcripts (on-targets). In practice, however, oligonucleotides may also bind to other transcripts, if these transcripts contain sequence regions very similar to the reverse complementary sequence of the oligonucleotide (off-targets). Various methods to evaluate (together with Jakob Rukov), and predict, on- and off-targets are being developed.

These projects lie within work package 4 (develop accessibility based RNA drug design algorithm), and work package 5 (reduce attrition of RNA drugs due to low tolerability), and contribute to the milestones Prediction of Safe RNA Drugs (mid-2014), and Prediction of Effective RNA Drugs (late-2014).

0 comments on “Peter Hagedorn
1 Pings/Trackbacks for "Peter Hagedorn"
  1. […] This explains why shorter and less affine oligonucleotides may sometimes be more potent. And Peter will present how the hepatotoxic potential of oligonucleotides can be predicted from their sequence […]

Leave a Reply